CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Remus Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Remus Pharmaceuticals Ltd
Phone: +91 7929999857p:+91 7929999857 AHMEDABAD, 380058  India Ticker: REMUSREMUS
Business Summary
Remus Pharmaceuticals Limited is engaged in marketing and distribution of finished formulations of pharmaceutical drugs. The Company also deals in active pharmaceutical ingredient (API). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. It deals in drug forms like capsules, cream, eye drops, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, sachet, suspension, tablet. The therapeutic areas it works include oncology, cardiovascular, anti-diabetic, immune suppressants, anti-biotic, antibacterial, dermatology, central nervous system, and others. Its oncology products include Sorafenib Tablets, Enzalutamide Capsules, Lenalidomide Capsule, and others. Its cardiovascular products include Rivaroxaban Tablets, Ticagrelor Tablets, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Swapnil J.Shah 37 1/16/2023 1/16/2023
Chief Financial Officer AnjaliShah 1/6/2023 1/6/2023
Compliance Officer, Company Secretary Deval B.Patel 1/6/2023 1/6/2023
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 48 (As of 3/31/2024)
Outstanding Shares: 5,892,000 (As of 9/30/2024)
Stock Exchange: NSE


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024